U.S. Physical Therapy, Inc. (USPH)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $1.49B
Last updated: Nov 17, 2026 at 11:05 AM ET
U.S. Physical Therapy, Inc. (USPH) Stock Forecast
Analysts expect U.S. Physical Therapy (USPH) to earn $2.88 per share in the fiscal year ending Dec 31, 2026, on revenue of $860.43M. Of 7 analysts, 6 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.57, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 57.1% |
| Buy | 2 | 28.6% |
| Hold | 1 | 14.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 16.0% and revenue estimates rise 8.5%.
- Fiscal year ending Dec 31, 2026
- $2.88
- EPS consensus, revenue $860.43M
- Fiscal year ending Dec 31, 2027
- $3.34
- EPS consensus, revenue $933.21M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.88 | $2.78 to $2.99 | 5 | $860.43M | $854.24M to $863.74M | 6 |
| Dec 31, 2027 | $3.34 | $3.03 to $3.61 | 5 | $933.21M | $909.26M to $968.00M | 7 |
Quarterly Estimates
The EPS consensus falls from $0.90 for the quarter ending Dec 31, 2026 to $0.54 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.90 | $0.76 to $1.04 | 9 | $233.73M | $214.95M to $262.95M | 9 |
| Mar 31, 2027 | $0.54 | $0.47 to $0.60 | 2 | $220.40M | $215.89M to $224.61M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 0.7% from $2.90.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.88 | $2.89 | $2.90 | $2.89 | $2.90 | -0.7% |
| Fiscal year ending Dec 31, 2027 | $3.34 | $3.33 | $3.35 | $3.31 | $3.42 | -2.3% |
| Quarter ending Mar 31, 2027 | $0.54 | $0.51 | $0.51 | $0.50 | $0.54 | -0.3% |
Frequently Asked Questions About USPH
What is the USPH stock forecast?
Consensus analyst estimates put U.S. Physical Therapy's EPS at $2.88 for the fiscal year ending Dec 31, 2026, on revenue of $860.43M. The consensus rating from 7 analysts is Buy.
How do analysts rate USPH stock?
Of 7 analysts covering U.S. Physical Therapy, 4 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from USPH next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.88, with estimates from $2.78 to $2.99 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.34, with estimates from $3.03 to $3.61 from 5 analysts.
What revenue do analysts expect from U.S. Physical Therapy next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $860.43M, with estimates from $854.24M to $863.74M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $933.21M, with estimates from $909.26M to $968.00M.
How many analysts cover USPH?
7 analysts rate U.S. Physical Therapy stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
USPH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors